Seeking Synergy of Checkpoint Blockade through TGFβ Inhibition.
Immunotherapy, including checkpoint blockade, is revolutionizing the treatment of cancers, but efficacy has, however, been limited to a subset of patients and can be of limited duration due to primary and acquired resistance to treatment. An article in this issue shows that inhibiting TGFβ can overcome resistance to blockade of one immune checkpoint, but not another, unless one follows where the mechanism leads.See article by Zhao et al., p. 1459.